Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

ConditionsCoronary Artery Disease Ischemic Mitral Regurgitation Angiotensin Receptor/Neprilysin Inhibitor

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age18+

SponsorChina National Center for Cardiovascular Diseases

About this trial

This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.

Eligibility criteria

Qualifiers

Fully informed and voluntarily signed informed consent;

Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards )

Disqualifiers

None

Trial design

Treatments tested in this trial

sacubitril/valsartan

Treatment groups

220 Participants

are divided into 2 treatment groups

Locations

China National Center for Cardiovascular Diseases100037, BeijingBeijing Municipality, China

Sponsors and collaborators

China National Center for Cardiovascular Diseases

Lead sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Collaborator

Chinese Academy of Medical Sciences

Collaborator

Source ClinicalTrials.gov